ASTRAVERUS Trademark

Trademark Overview

On Thursday, July 9, 2026, a trademark application was filed for ASTRAVERUS with the United States Patent and Trademark Office. The USPTO has given the ASTRAVERUS trademark a serial number of 99930639. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, July 9, 2026. The ASTRAVERUS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing independent review and monitoring of clinical trials for safety compliance; Monitoring clinical trials for safety purposes; Independent clinical safety review and assessment of clinical trial data
astraverus

General Information

Serial Number99930639
Word MarkASTRAVERUS
Filing DateThursday, July 9, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, July 9, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesProviding independent review and monitoring of clinical trials for safety compliance; Monitoring clinical trials for safety purposes; Independent clinical safety review and assessment of clinical trial data

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 9, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressOrlando, FL 34786
US

Trademark Events

Event DateEvent Description
Thursday, July 9, 2026NEW APPLICATION ENTERED
Thursday, July 9, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

astraverus clinical safety monitoring trials review independent trial data assessment compliance